References
1. United Kingdom Diabetes study group, United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ, 1995. 310(6972):83–8.
2. Diamanti-Kandarakis E, Economou F., Palimeri S, Christakou C, Metformin in polycystic ovary syndrome. Ann N Y Acad Sci. 2010;1205:192–8.
3. Bianchi C, Penno G, Romero F, Del Prato S, Miccoli R. Treating the metabolic syndrome. Expert Rev Cardiovasc Ther. 2007;5(3):491–506.
4. Knowler WC, Barett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med.2002;346(6):393–403.
5. LeRoith D, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
6. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3:1066-76.
7. Schmelzle T, Hall M. TOR, a central controller of cell growth.Cell. 2000;103(2):253–62.
8. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115 (5):577–90.
9. Gwinn DM, Shackelford D, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphor-ylation of raptor mediates a metabolic checkpoint. Moll Cell.2008;30(2): 214–26.
10. R. J. Dowling, P. J. Goodwin and V. Stambolic, “Under- standing the Benefit of Metformin Use in Cancer Treat- ment,” BMC Medicine, Vol 9,No 33,2011,pp. 1-6.
11. Liang J, Shao S, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 2007;9(2):218–24.
12. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxiaind-ucible factor 1alpha expression and function by the mammalian target of rapamycin. Moll Cell Biol. 2002;22 (20):7004–14.
13. Majumder PK, Febbo P, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10(6):594–601.
14. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–73..
15. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909–15.
16. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8 (13):2031–40.
17. Yang XR, So M, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcı´a-Closas M. Differences in risk factors for breast cancer molecular subtypes in a population- based study. Cancer Epidemiol Biomarkers Prev. 2007; 16(3):439–43.
18. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–9.
19. Albanes D, Weinstein S, Wright ME, Ma¨nnisto¨ S, Limburg PJ, Snyder K, Virtamo J. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst.2009;101 (18):1272–9.
20. Gunter MJ, Hoover D, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC,Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD.Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48–60.
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.97
